Mostrar el registro sencillo del ítem

dc.contributor.authorLlueca, Antoni
dc.contributor.authorSerra Rubert, Anna
dc.contributor.authorHerraiz, José Luis
dc.contributor.authorRivadulla, Isabel
dc.contributor.authorGómez-Quiles, Luis
dc.contributor.authorGilabert-Estellés, Juan
dc.contributor.authorEscrig-Sos, Javier
dc.date.accessioned2018-06-18T11:23:39Z
dc.date.available2018-06-18T11:23:39Z
dc.date.issued2018
dc.identifier.issn1178-6930
dc.identifier.urihttp://hdl.handle.net/10234/175249
dc.description.abstractObjective: To analyze the surgical outcomes and diaphragmatic involvement in stage III and IV ovarian cancer. Patients and methods: All patients with stage III–IV ovarian cancer between January 2013 and January 2016 were included. The outcomes of interest reviewed were as follows: surgical (complications, mortality), peritoneal carcinomatosis index (PCI), rate of complete resection, and disease-free interval and survival. Results: Fifty-seven patients were included, 38 (67%) with diaphragmatic involvement; in 10 cases (18%), diaphragmatic resection was required. Optimal cytoreduction (OCR) was obtained in 49 cases (86%). The PCI was .10 in 31 cases (54%). Respiratory complications occurred in 10 cases (18%) and mortality in 3 (5%). Disease-free survival rate in 3 years was 53%, being 87% in cases without diaphragmatic involvement. The overall survival rate in 3 years is 46%, 83% in the cases without diaphragmatic involvement and 27% in cases with affectation (p,0.05). In cases of OCR, 3 year survival rate was 65%. In the multivariate analysis for the overall survival of cases with OCR, the only independent prognostic factor found was the operative PCI. A strong correlation was found between the total PCI and the diaphragmatic PCI (p,0.001). With a PCI .10, virtually all cases will present diaphragmatic involvement (p,0.05). Conclusion: The tumor burden is different in stages III and IV of advanced ovarian cancer and the PCI is an effective method to quantify it. The PCI constitutes an independent prognostic factor for the advanced stages of ovarian cancer. A PCI .10 constitutes a useful prognostic factor of the affectation and forces the surgeon to thoroughly review both diaphragms.ca_CA
dc.format.extent7 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherDove Medical Pressca_CA
dc.relation.isPartOfOncoTargets and Therapy 2018:11ca_CA
dc.rights© 2018 Llueca et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)ca_CA
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectadvanced ovarian cancerca_CA
dc.subjectperitoneal cancer indexca_CA
dc.subjectdiaphragmatic involvementca_CA
dc.subjectupper abdominal surgeryca_CA
dc.subjectcarcinomatosisca_CA
dc.titlePeritoneal carcinomatosis index as a predictor of diaphragmatic involvement in stage III and IV ovarian cancerca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttp://dx.doi.org/10.2147/OTT.S147559
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.relation.publisherVersionhttps://www.dovepress.com/peritoneal-carcinomatosis-index-as-a-predictor-of-diaphragmatic-involv-peer-reviewed-article-OTTca_CA
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_CA


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

© 2018 Llueca et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0/). By accessing the work you
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)
Excepto si se señala otra cosa, la licencia del ítem se describe como: © 2018 Llueca et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)